Analysts Set Expectations for Moderna FY2029 Earnings

Moderna, Inc. (NASDAQ:MRNA) – Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for Moderna in a report issued on Monday, January 13th. Brookline Capital Management analyst L. Cann expects that the company will post earnings of $22.02 per share for the year. The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the company earned ($1.39) earnings per share.

Several other brokerages have also recently issued reports on MRNA. Piper Sandler restated an “overweight” rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a research note on Monday, November 18th. Berenberg Bank initiated coverage on Moderna in a research report on Tuesday, November 19th. They set a “hold” rating and a $42.00 price target on the stock. Sanford C. Bernstein assumed coverage on Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price objective for the company. Finally, Leerink Partners lowered their target price on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. Four investment analysts have rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Moderna presently has an average rating of “Hold” and an average target price of $78.83.

Moderna Price Performance

Shares of MRNA stock opened at $34.46 on Wednesday. The firm has a fifty day moving average of $41.78 and a two-hundred day moving average of $67.79. The firm has a market cap of $13.26 billion, a P/E ratio of -5.92 and a beta of 1.60. Moderna has a 1-year low of $31.94 and a 1-year high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MRNA. State Street Corp lifted its position in shares of Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after buying an additional 1,823,276 shares during the last quarter. Wellington Management Group LLP boosted its position in Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares during the period. Two Sigma Advisers LP acquired a new position in Moderna during the third quarter valued at approximately $23,825,000. International Assets Investment Management LLC raised its position in shares of Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after purchasing an additional 316,552 shares during the period. Finally, Douglas Lane & Associates LLC lifted its stake in shares of Moderna by 62.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock worth $32,175,000 after buying an additional 298,715 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold 2,664 shares of company stock worth $115,210 in the last 90 days. Company insiders own 15.70% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.